Li-Long Pan1, Wenjie Liang2,3, Zhengnan Ren2,3, Chunqing Li4, Yong Chen5, Wenying Niu1, Xin Fang1, Yanyan Liu2,3, Ming Zhang2,3, Julien Diana6, Birgitta Agerberth7, Jia Sun2,3. 1. Wuxi School of Medicine, Jiangnan University, Wuxi, China. 2. Laboratory of Nutritional Immunology and Translational Medicine, State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China. 3. School of Food Science and Technology, Jiangnan University, Wuxi, China. 4. Department of Nephrology, Affiliated Hospital of Jiangnan University, Wuxi, China. 5. Department of Nephrology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China. 6. Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1151, Institute Necker-Enfants Malades (INEM), Centre National de la Recherche Scienctifique, Unité 8253, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 7. Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, F68, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Abstract
BACKGROUND AND PURPOSE: Despite recent advances in understanding its pathophysiology, treatment of acute kidney injury (AKI) remains a major unmet medical need, and novel therapeutic strategies are needed. Cathelicidin-related antimicrobial peptide (CRAMP) with immunomodulatory properties has an emerging role in various disease contexts. Here, we aimed to investigate the role of CRAMP and its underlying mechanisms in AKI. EXPERIMENTAL APPROACH: The human homologue LL-37 and CRAMP were measured in blood samples of AKI patients and in experimental AKI mice respectively. Experimental AKI was induced in wild-type and CRAMP-deficient (Cnlp-/- ) mice by ischaemia/reperfusion (I/R). Therapeutic evaluation of CRAMP was performed with exogenous CRAMP (5 mg·kg-1 , i.p.) treatment. KEY RESULTS: Cathelicidin expression was inversely related to clinical signs in patients and down-regulated in renal I/R-induced injury in mice. Cnlp-/- mice exhibited exacerbated I/R-induced renal dysfunction, aggravated inflammatory responses and apoptosis. Moreover, over-activation of the NLRP3 inflammasome in Cnlp-/- mice was associated with I/R-induced renal injury. Exogenous CRAMP treatment markedly attenuated I/R-induced renal dysfunction, inflammatory response and apoptosis, correlated with modulation of immune cell infiltration and phenotype. Consistent with Cnlp-/- mouse data, CRAMP administration suppressed renal I/R-induced NLRP3 inflammasome activation, and its renal protective effects were mimicked by a specific NLRP3 inhibitor CY-09. The reno-protective and NLRP3 inhibitory effects of CRAMP required the EGF receptor. CONCLUSION AND IMPLICATIONS: Our results suggest that CRAMP acts as a novel immunomodulatory mediator of AKI and modulation of CRAMP may represent a potential therapeutic strategy.
BACKGROUND AND PURPOSE: Despite recent advances in understanding its pathophysiology, treatment of acute kidney injury (AKI) remains a major unmet medical need, and novel therapeutic strategies are needed. Cathelicidin-related antimicrobial peptide (CRAMP) with immunomodulatory properties has an emerging role in various disease contexts. Here, we aimed to investigate the role of CRAMP and its underlying mechanisms in AKI. EXPERIMENTAL APPROACH: The human homologue LL-37 and CRAMP were measured in blood samples of AKIpatients and in experimental AKImice respectively. Experimental AKI was induced in wild-type and CRAMP-deficient (Cnlp-/- ) mice by ischaemia/reperfusion (I/R). Therapeutic evaluation of CRAMP was performed with exogenous CRAMP (5 mg·kg-1 , i.p.) treatment. KEY RESULTS: Cathelicidin expression was inversely related to clinical signs in patients and down-regulated in renal I/R-induced injury in mice. Cnlp-/- mice exhibited exacerbated I/R-induced renal dysfunction, aggravated inflammatory responses and apoptosis. Moreover, over-activation of the NLRP3 inflammasome in Cnlp-/- mice was associated with I/R-induced renal injury. Exogenous CRAMP treatment markedly attenuated I/R-induced renal dysfunction, inflammatory response and apoptosis, correlated with modulation of immune cell infiltration and phenotype. Consistent with Cnlp-/- mouse data, CRAMP administration suppressed renal I/R-induced NLRP3 inflammasome activation, and its renal protective effects were mimicked by a specific NLRP3 inhibitor CY-09. The reno-protective and NLRP3 inhibitory effects of CRAMP required the EGF receptor. CONCLUSION AND IMPLICATIONS: Our results suggest that CRAMP acts as a novel immunomodulatory mediator of AKI and modulation of CRAMP may represent a potential therapeutic strategy.
Authors: Oliver Soehnlein; Sarawuth Wantha; Sakine Simsekyilmaz; Yvonne Döring; Remco T A Megens; Sebastian F Mause; Maik Drechsler; Ralf Smeets; Stefan Weinandy; Fabian Schreiber; Thomas Gries; Stefan Jockenhoevel; Martin Möller; Santosh Vijayan; Marc A M J van Zandvoort; Birgitta Agerberth; Christine T Pham; Richard L Gallo; Tilman M Hackeng; Elisa A Liehn; Alma Zernecke; Doris Klee; Christian Weber Journal: Sci Transl Med Date: 2011-10-05 Impact factor: 17.956
Authors: Rokeya Sultana Rekha; S S V Jagadeeswara Rao Muvva; Min Wan; Rubhana Raqib; Peter Bergman; Susanna Brighenti; Gudmundur H Gudmundsson; Birgitta Agerberth Journal: Autophagy Date: 2015 Impact factor: 16.016
Authors: Bing-Qing Deng; Ying Luo; Xin Kang; Chang-Bin Li; Christophe Morisseau; Jun Yang; Kin Sing Stephen Lee; Jian Huang; Da-Yong Hu; Ming-Yu Wu; Ai Peng; Bruce D Hammock; Jun-Yan Liu Journal: Proc Natl Acad Sci U S A Date: 2017-11-06 Impact factor: 11.205